Vascular Biogenics Ltd (VBLT)

[wcopeland]

Thanks for the share gr8. I imagine the Avastin approval was a combination of several things - such as intentionally designing their trial to receive favorable results, few competitors, our lack of scientific knowledge, and a poor understanding of the impact of measuring different endpoints (ie. PFS is more or less meaningless).

On the one hand, it is a shame that Roche flooded the market with a poor efficacy drug. It is also a shame that biosimilars of that subpar drug are going to be peddled by the likes of Amgen.

On the other hand, the fact that no other drug has supplanted Avastin in a head-to-head randomized Ph3 should remind us of the difficulty of this indication.

"... and hopefully VB-111 does too." EXACTLY! In several months, the whole world will learn that VB-111 is a transformative therapy for those with rGBM. I am still excited!